AMGEN

† Analysis from 2022 to 2023 for Commercial and Medicare patient claims combined. Data based on IQVIA LAAD claims data. Oral OOP percent is a weighted average of claims for eltrombopag, avatrombopag, and fostamatinib disodium hexahydrate... The information provided in this section is intended expressly for healthcare professionals in the United States. Click "Yes, I am" to enter if you are a U... * Remission was a secondary objective in the Nplate® clinical study. It occurred in 32% of patients (24 out of 75) and was defined as keeping platelet counts of at least 50,000 for at least 6 months while off treatment. The main objective of the study was to look at how platelet count responded to Nplate®.

Also known as: Amgen Inc, platelet booster